<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525653</url>
  </required_header>
  <id_info>
    <org_study_id>15-054</org_study_id>
    <nct_id>NCT02525653</nct_id>
  </id_info>
  <brief_title>Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers</brief_title>
  <official_title>A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and effectiveness of albumin-bound
      paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The
      investigators would like to determine the percentage of patients with squamous cell lung
      cancers who experience shrinkage of their tumors following treatment with this regimen. This
      combination of drugs is not a standard therapy for patients with squamous cell lung cancers.
      However, each of these drugs, when given alone or with other chemotherapies, is FDA-approved
      for the treatment of this disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>best objective response (BOR) rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>defined as the proportion of patients with complete or partial responses based on RECIST 1.1, at any time prior to disease progression, out of all evaluable patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity data (AEs, laboratory data and vital sign data)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>(AEs, laboratory data and vital sign data) will be collected, tabulated according to CTCAE version 4.0 and summarized using descriptive statistics. Adverse events will be listed individually per patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Untreated Stage IV or Recurrent Squamous Cell Lung Cancers</condition>
  <arm_group>
    <arm_group_label>Albumin-Bound Paclitaxel and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each 28-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1, 8, and 15 of each 28 day cycle. A total of six cycles will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin-bound paclitaxel</intervention_name>
    <arm_group_label>Albumin-Bound Paclitaxel and Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <arm_group_label>Albumin-Bound Paclitaxel and Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed squamous cell lung cancer

          -  Recurrent and/or Stage IV squamous cell lung cancer who have never been treated with
             systemic therapy for metastatic disease

          -  Measurable disease as per RECIST 1.1

          -  Greater than 6 months since receiving neo-adjuvant or adjuvant chemotherapy.

          -  Age ≥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Women of childbearing potential and sexually active men enrolled in the study must
             agree to practice effective contraception method during treatment and for three
             months after completing treatment

          -  Negative serum or urine β-hCG pregnancy test at screening for patients of
             childbearing potential

          -  &lt; Grade 2 pre-existing peripheral neuropathy (per CTCAE)

          -  Marrow and organ function as follows:

          -  ANC ≥ 1500 cells/mm3

          -  Platelets &gt; 100,000 cells/mm3

          -  Hemoglobin&gt;9g/dL

          -  Creatinine clearance ≥ 40mL/min

          -  Bilirubin ≤ 1.5 mg/dL

          -  AST/ALT≤2.5 x upper limit of normal range (ULN),

          -  alkaline phosphatase ≤ 2.5 X upper limit of normal, unless bone metastasis in present
             in the absence of liver metastasis

        Exclusion Criteria:

          -  Prior treatment with albumin-bound paclitaxel or gemcitabine

          -  Prior systemic anticancer therapy for advanced squamous cell lung cancer

          -  Untreated brain metastasis. Patients with treated brain metastases who are off
             steroids are eligible

          -  Peripheral neuropathy greater than grade 1

          -  Malignancies within the past 5 years other than non-melanoma skin cancer or insitu
             cervical cancer status post treatment

          -  Patients with other serious medical illnesses including, ongoing or active infection,
             unstable angina pectoris, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Class III or IV congestive heart failure by New York Heart Association
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Paik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Paik, MD</last_name>
    <phone>646-888-4202</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kenneth Ng, MD</last_name>
    <phone>516-256-3651</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-888-4202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-888-4202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-888-4202</phone>
    </contact>
    <contact_backup>
      <last_name>Kenneth Ng, MD</last_name>
      <phone>516-256-3651</phone>
    </contact_backup>
    <investigator>
      <last_name>Paul Paik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-888-4202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-888-4202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering West Harrison</name>
      <address>
        <city>West Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Paik, MD</last_name>
      <phone>646-888-4202</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 8, 2016</lastchanged_date>
  <firstreceived_date>August 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Albumin-Bound</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>15-054</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
